Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...
If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback